Compounds > 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Page last updated: 2024-09-02

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Neoplasms

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with Neoplasms in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19903 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benjamin, RS; Bodey, GP; Burgess, MA; Gottlieb, JA; Keating, MJ; Livingston, RA; McCredie, KB; Rodriguez, V; Valdivieso, M1
Marles, A; Mason, KA; Peters, LJ1
Klahr, C; Presant, CA1

Trials

1 trial(s) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Neoplasms

ArticleYear
Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia.
    Cancer treatment reports, 1979, Volume: 63, Issue:6

    Topics: Adult; Antibiotics, Antineoplastic; Bone Marrow; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Melanoma; Neoplasms; Piperazines

1979

Other Studies

2 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Neoplasms

ArticleYear
The critical influence of timing of combined modality cytoreductive regimens.
    Experimental hematology, 1979, Volume: 7 Suppl 5

    Topics: Animals; Bone Marrow; Cell Survival; Drug Administration Schedule; Humans; Intestines; Mice; Neoplasms; Piperazines; Whole-Body Irradiation

1979
Severe myelosuppression from piperazinedione, (NSC No. 135758), cyclophosphamide plus dimethyl-triazeno-imidazole carboxamide (DTIC).
    Cancer, 1977, Volume: 40, Issue:4

    Topics: Bone Marrow; Cyclophosphamide; Dacarbazine; Drug Therapy, Combination; Humans; Neoplasms; Piperazines; Piperidines; Triazenes

1977